Nurix Therapeutics Files 8-K on Financials

Ticker: NRIX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1549595

Sentiment: neutral

Topics: financial-condition, results-of-operations, disclosure

Related Tickers: NRIX

TL;DR

Nurix dropped an 8-K on Jan 13th covering financials and operations.

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company, previously known as Nurix, Inc., is incorporated in Delaware and headquartered in San Francisco, California.

Why It Matters

This 8-K filing provides crucial updates on Nurix Therapeutics' financial health and operational status, which is important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Nurix Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report on Nurix Therapeutics, Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements.

On what date was this 8-K report filed?

This 8-K report was filed on January 13, 2025.

Where are Nurix Therapeutics, Inc.'s principal executive offices located?

Nurix Therapeutics, Inc.'s principal executive offices are located at 1700 Owens Street, Suite 205, San Francisco, California 94158.

In which state is Nurix Therapeutics, Inc. incorporated?

Nurix Therapeutics, Inc. is incorporated in Delaware.

What was Nurix Therapeutics, Inc.'s former company name?

Nurix Therapeutics, Inc.'s former company name was Nurix, Inc.

Filing Stats: 933 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-01-13 07:02:18

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Nurix Therapeutics, Inc. (the "Company") will present an investor presentation at the 43rd Annual J.P. Morgan Healthcare Conference (the "JPM Conference"), which reports the preliminary, unaudited amount of the Company's cash, cash equivalents and marketable securities position as of November 30, 2024, as $609.6 million, and reports that, based on its current operating plan, the Company expects that it will be able to fund its operating activities into the first half of 2027. This estimated, unaudited cash, cash equivalents and marketable securities amount has been prepared by management and is based upon information available to management as of the date of this Current Report on Form 8-K. This amount is subject to the completion of financial closing procedures that could result in changes to the amount. Furthermore, this amount does not present all information necessary for a complete understanding of the Company's financial condition as of or for the fiscal year ended November 30, 2024. The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed any procedures with respect to this preliminary financial data and, accordingly, does not express an opinion or any other form of assurance with respect thereto. The Company's audited results as of and for the year ended November 30, 2024, will be included in the Company's Annual Report on Form 10-K for the year ended November 30, 2024. The information furnished with this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In addition to the Company's presentation at the JPM Conference, on January 13, 2025, the Company issued a press release regarding its performance in 2024 and its major goals for 2025. A copy of the Company's press release and its presentation materials for the JPM Conference are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. press release dated January 13 , 202 5 . 99.2 Nurix Therapeutics, Inc. investor presentation dated January 13 , 202 5 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing